Company news

Summit Therapeutics Inc. news in 2023

Summit Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.

View company

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023

November 6, 2023

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

November 1, 2023

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

November 1, 2023

Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

October 30, 2023

Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023

October 25, 2023

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

October 18, 2023

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

October 15, 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

August 8, 2023

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

August 1, 2023

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

June 3, 2023

Ivonescimab Updated Data to be Featured at ASCO 2023

May 31, 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

May 10, 2023

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

May 8, 2023

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

May 2, 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

March 8, 2023

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

March 2, 2023

Summit Therapeutics’ Rights Offering Nearing Expiration Date

February 22, 2023

Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

January 29, 2023

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

January 19, 2023

Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Calls in 2023

Decks in 2023